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ABSTRACT
Several large cohort studies have disclosed the trajectories of sex steroids changes overtime in
men and their clinical significance. In men the slow, physiological decline of serum testosterone
(T) with advancing age overlaps with the clinical condition of overt, pathological
hypogonadism. In addition, the increasing number of comorbidities, together with the high
prevalence of chronic diseases, all further contribute to the decrease of serum T concentrations
in the aging male. For all these reasons both the diagnosis of late-onset hypogonadism (LOH) in
men and the decision about starting or not T replacement treatment remain challenging. At
present, the biochemical finding of T deficiency alone is not sufficient for diagnosing
hypogonadism in older men. Coupling hypogonadal symptoms with documented low serum T
represents the best strategy to refine the diagnosis of hypogonadism in older men and to avoid
unnecessary treatments.
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Introduction
Aging is associated with changes in the physiological
functioning of the endocrine system.1 Except for the thy-
rotropin hormone (TSH) that tends to increase with
advancing age, the secretion of other pituitary hormones
such as growth hormone (GH) and prolactin progres-
sively decreases with aging.1 The same happens to insu-
lin-like growth factor-1 (IGF-1), which is directly
regulate by GH.1
The aging of the reproductive function is character-
ized by the loss of function of gonads that occurs as an
on/off phenomenon in females at the time of meno-
pause.1,2 (Fig. 1). Vice versa, in aging males, the repro-
ductive function progressively declines in parallel with
the decrease of testicular function year by year1 Accord-
ingly, gonadotropins slightly increase in men while defi-
nitely soar at the time of menopause in women.1 In men,
however, also a decline of gonadotropic cell function has
been documented in a significant percentage of aging
men.3
As far as sex hormones are concerned, it should be
remarked that their production is different in men and
women during adulthood: serum testosterone (T) is 10
folds higher in men than in women, while serum estra-
diol (E2) declines after the fifties in both sexes; thus sex
hormones changes during aging differ by gender (Fig. 1).
Gender differences in aging related decline of sex hor-
mones are outlined in Figure 1.
Physiological decline of serum T with advancing age
in men
Serum total T declines with advancing age with a rate
that has been estimated to be about 1–2% per year from
the third decade onward.4,5 (Fig. 1). This rate of decline
in serum T corresponds approximately to a reduction of
3.2–3.5 ng/dL (0.110–0.121 nmol/L) per year4,6 At the
age of 75 y a men has already lost about 30% of his circu-
lating quote of T measured at the age of 25 years.5,7
According to different studies, the prevalence of low total
T in men over 60 y is, on average, around 20% to 30%
and it constantly increases with aging.3-5,8-10
The total amount of circulating serum T corresponds
to the total serum T usually assayed into the clinic, which
is the sum of both free T and T bound to serum pro-
teins.11 Serum free T represents the circulating fraction
that is completely unbound and promptly available for
binding the androgen receptor in target tissues; it is,
however, a small part of circulating serum T11. A mini-
mal part of circulating T bounds albumin and the
strength of this binding is weak.11 For this reason, serum
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free T and T bound to albumin—in other words the T
not bound to Sex Hormone Binding Globulin
(SHBG)—represent the bioavailable T11. Vice versa T
bound to SHBG is not promptly available for binding
the androgen receptor due to the high strength of the
binding; this represents the amount of circulating T
which is not bioavailable.7,,11-14 Since bioavailable serum
T is more available to the cells compare with SHBG-
bound serum T, information on changes in both serum
free and bioavailable T during aging is of relevance.14
SHBG increases with advancing age of about 2.7% per
year,4,15,16 and accounts for an even larger decline in
serum bioavailable T (3 to 4% per year) compare with
total T in the elderly man.5 In addition, several factors
(e.g. obesity)17-20 and/or comorbidities,21,22 which
become common with advancing age, might modify in
percentage amount amount of different T fractions.7
Several methods are available to measure the different
fractions of circulating T. Total serum T is the fraction
most commonly measured in clinical practice and is usu-
ally assayed with Immunoassays (IAs) in clinical labora-
tories.12,23-25 Mass spectrometry (MS), particularly liquid
chromatography-tandem mass spectrometry (LC-MS/
MS),26 is considered the gold standard for the measure-
ment of total serum T, but, at present, is mainly used for
research purposes.23,27 In general, results obtained with
IAs do not reproduce in a reliable way those obtained
with LC-MS/MS28 leading to the concept that commer-
cially available IAs are widely inaccurate if compared
with the gold standard.24,27-30 Accordingly, LC-MS/MS
is able to lessen interferences, has better specificity, and
reduce between-method bias.31 However, different
results obtained by using different IAs are unimportant
in the male, eugonadal range, but becomes relevant
when measuring T levels falling in the low male
range.23,27 In discordance with other studies,27 the com-
parison between serum total T measurements by using
IAs or MS, which represents the gold standard for T lev-
els measurement, has shown similar, highly-correlated
results in the EMAS cohort.32 This means that IAs could
be considered a good method for the evaluation of total
serum T in clinical practice also for distinguishing
between eugonadism and hypogonadism in the clinical
setting.32 This issue is crucial for the diagnosis of male
hypogonadism and is still controversial (see the para-
graph below on the diagnosis of male hypogonadism in
aging). In general, for clinical purposes it is important to
validate the assay and to perform continuous quality
control, independently from the methodology
used.23,29,30,33 Furthermore, in the last few years, LC-MS/
MS is becoming more and more available in the clinical
setting and this evolving scenario is expected to be
implemented, especially in clinical laboratories able to
provide high throughput outcomes thanks to the proce-
dural low costs that allows saving money for each assay
and writing off expenses due to initial purchase of tech-
nological equipments.23
The measurement of free serum T might be per-
formed by means of equilibrium dialysis or ultrafiltration
methods, which are, however, not manageable in clinical
practice or, alternatively, by the use of direct free T
assays, which are unreliable and strongly inaccurate.23,24
The better way to have an esteem of free serum T is to
calculate free serum T starting from the value of total
serum T and the measurement of both SHBG and albu-
min.7,13,23,24 Even though it is well known that calculated
free T overestimates the value obtained by equilibrium
dialysis,14 it remains largely employed both for research
and clinical purposes.
Techniques for the measurement of bioavailable
serum T are based on previous precipipation and separa-
tion of SHBG-bound T. For this reason, these methods
are not simple and are not routinely employed in clinical
laboratories. In addition, it is not clear the advantage of
measuring bioavailable T rather than free T23. Starting
from available data of serum albumin, SHBG, and total
T, it is possible to calculate free and bioavailable serum T
by using a simple formula and a calculator widely avail-
able on the web (http://www.issam.ch/freetesto.htm). By
taking into account all the issues mentioned before, it
becomes clear that the comparison of the results coming
from different studies suffers from bias due to methodo-
logical differences when measuring serum T and its
decline during aging.
As serum T varies during the day34 and season-
ally,25,35,36 it should be assayed in the morning and low
Figure 1. Serum levels of both testosterone (T) (solid lines) and
estradiol (E2)
 (broken lines) across the lifespan in men (blue
lines) and women (pink lines). Data used for plotting age-related
sex steroids changes in both sexes have been derived from Kauf-
man & Vermeulen 20055, Zmuda et al. 19976 (for men), and from
Al-Safi et al. 20002 and Veldhuis 2013 (for women). serum E2 levels
of premenopausal women are represented as the mean of E2 mea-
sured during the different phases of the menstrual cycle; T: testos-
terone; E2: estradiol.
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values need to be confirmed twice in 2 different serum
samples, the second one being obtained at least after 2 to
4 weeks after first T determination.12,25 Differences in
timing serum samples for T determination might also
account for discrepant results obtained in different
research settings.
In addition, the decline of both total and free serum T
shows of course a high degree of interindividual variabil-
ity5 accounting for serum T within the normal range in
most of the elderly patients (>60 years) and below the
normal range in about 20% of them.37
Several risk factors have been associated with serum T
decline.38-40 Among them ethnicity, age, anthropometry,
lifestyle factors, other concomitant comorbidities,
chronic diseases, critical acute illnesses, drugs and/or
other treatments should be taken into account.15,41 The
main risk factors or clinical conditions associated with
low serum T are listed in Table 1.
Relationship between T decline and estradiol E2
Longitudinal studies have shown that serum E2 declines
in parallel with serum T in men.3,32,37 It is well known
that serum E2 rather than T is important for bone
health.42 Thus, the decline of serum T in older men
becomes particularly harmful for the bone only when
also serum E2 decreases. In particular serum E2 should
decrease below a threshold which is in-between 15 and
25 pg/mL (55.1–91.8 pmol/L).42,43
Apart from the role of E2 on bone, other several physi-
ological functions have been attributed mainly to E2.
Among them, the inhibitory effect of T on the hypothala-
mus and the pituitary seems to be due to a greater extent
to its conversion into estrogens.44,45 Furthermore, also
sexual function, especially sexual desire, is in part depen-
dent from E2 too.
45,46 Accordingly, serum E2 is directly
related to sexual desire in men.47
At present less is known about the E2 interindividual
differences in serum among men with hypogonadism.
However, it is possible to hypothesize that hypogonadal
men with a higher aromatase activity might be protected
from the decrease of E2 when their serum T declines.
48
E2 plays an important role also in the relationship
between hypogonadism and obesity since the increased
production of estrogens within the fat tissue contributes
to inhibit luteinizing hormone (LH) secretion from the
pituitary and to reduce T secretion from the testes.49
This mechanism could be involved not only in older
men with hypogonadism, but also in other clinical condi-
tions characterized by fat redistribution (e.g., Human
Immunodeficiency Virus [HIV] infection).50
The measurement of serum E2, however, is not useful
in clinical practice since the accuracy of IAs commonly
used in the clinical laboratories is poor for the low values
typical of the male range.51
Age-related male hypogonadism: Results from large
cohorts studies involving middle-aged to older men
One of the first studies investigating serum T in aging
men by a longitudinal design was the New Mexico Pro-
cess Study52 that followed preliminary data previously
obtained by cross-sectional studies.53-56 Previous data
were contradictory and came from observational studies
mainly based on inpatients with a poor health status,
thus they were not representative on average of an aging
population of men.37,54,57 After the above mentioned
study, several other studies on large cohort of aging men
were prospectively performed. Of them, the main are:
the Baltimore Longitudinal Study of Aging (BLSA), the
Massachusetts Male Aging Study (MMAS), the Osteopo-
rotic Fractures in Men Study (MrOS), the European
Male Aging Study (EMAS), the Rancho Bernardo Study
(RBS), the InCHIANTI Study, the Tromsø Study, the
Concord Health and Aging in Men Project (CHAMP),
the Health in Men Study (HIMS). The main characteris-
tics of these studies are all summarized in Table 2. All
these studies differ each other for several aspects, includ-
ing the main aim of the study (that not always is specifi-
cally addressed to the study of sex hormones decline
during aging), the involvement of subjects of both gen-
ders, the duration of the study, and the number of partic-
ipants (Table 2). As expected, also the methodological
approach differ among studies both in terms of methods
used for the assessment of circulating sex steroids, the
type of sex steroid assayed (estradiol is not available
from all the studies), the study design, and the clinical
investigations included in the study protocol, the latter
varying widely among studies according to their primary
and secondary endpoints (Table 3, Table 4). Even though
Table 1. Risk factors involved in serum T decline in aging men.
Risk factors and predictors of T deficiency:
General factors: Age, ethnicity, poor health status and frailty, progressive
decrease of number and function of Leydig cells.
Metabolic and and anthropometric factors: BMI, weight, waist
circumference, visceral adiposity.
Life-style habits: excessive alcohol intake, cigarette smoking, sedentary
lifestyle.
Comorbidities: hypertension, metabolic syndrome.
Chronic Diseases: moderate to severe chronic obstructive pulmonary disease,
HIV, chronic liver diseases, chronic renal failure (especially end-stage and
hemodyalisis), type 2 diabetes, hypopituitarism, reumatoid arthritis,
Hodgkin disease.
Critical Acute illness
Pharmacological and other treatments: opiates, glucocorticoids, inhibitors
of T synthesis (e.g., mitotane, ketoconazole), chemotherapy, testicular
irradiation, GnRH analogs
Note. T: testosterone; BMI: body mass index; GnRH: gonadotropin-releasing
hormone.
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the comparison among all these studies goes beyond the
aim of this review, we will try to report in a critical fash-
ion the aspects that are more relevant for the compre-
hension of the relationship between sex hormones and
aging in males.
Main characteristics of large cohort studies
The BLSA is a longitudinal study on human aging, which
begun in 1958 (https://www.blsa.nih.gov/about/history/);
it is the oldest study taking into account sex steroids
changes during aging in men and is based on enrollment
of participants with different ages who are followed after-
ward all lifelong.58 This is one of the biggest studies on
aging showing T levels decline in men and its relation-
ship with several aspects related to aging4 (Table 2).
Other than BLSA, also the RBS and the Tromsø Study
are very old, being started in the 70s (Table 2).59,60
Among studies that have specifically investigated the
decline of sex steroids, particularly T, in middle-aged to
older men, the MMAS is one of the pioneering study, the
investigation of sex hormones changes in aging being the
main study endpoint (Table 2).53,61 The MrOS study is a
multicenter study enrolling around 6000 men older than
65 y in order to identify risk factors for fractures in older
men (Table 2).62 By enrolling men also from Sweden and
Hong Kong, the study has reached a considerable num-
ber of participants (Table 2). The main aim of the study,
however, was to evaluate the association between sex
hormones levels and osteoporosis rather than overtime
changes during aging (Table 2).62
The EMAS (http://www.emas.man.ac.uk) is a multi-
center (involving 8 European centers) cohort study that
has been pointedly designed in order to evaluate physi-
cal, psychological and endocrine changes overtime, with
particular attention to modifications of T secretion
occurring with aging.63,64 (Table 2).
The Rancho Bernardo Study started as a survey of
heart disease risk factors in adults who were older than
30 y and lived in the southern California community of
Rancho Bernardo, that has progressively accumulated a
lot of data (not only on CV system) from this cohort
across the last 40 years59,65 (Table 2).
The InCHIANTI study involves older people living in the
Chianti geographic area (Tuscany, Italy) (http://inchian
tistudy.net/wp/). For the majority of men, measurements
of total T, E2 and SHBG serum levels were available,
even though the main aim of the study was not strictly
related to hormonal changes overtime66-70 (Table 2).
The Tromsø study (https://en.uit.no/prosjekter/
prosjekt?p_document_idD80172) is composed by several
surveys performed in sequence and collecting informa-
tion that have changed overtime across different sur-
veys60,71,72 The fourth survey was taken between 1994 and
1995; all inhabitants of Tromsø (Northern Norway) older
than 24 y were invited and, between the subjects who
accepted to take part to the study, all men aged 55–74 y
and random samples of the other age groups were involved
and hormonal measurements performed60 (Table 2).
The CHAMP study was originally designed in order
to investigate the health status in men older than 70 y liv-
ing in a defined geographical region near the Concord
Hospital in Sydney.73-75 The study paid particular atten-
tion to the effects of age-related sex hormones decline.73
After a baseline assessment; a subsequent, biennial follow
up was then realized.73 A strength of this project is the
use of LC-MS/MS for steroid assays, which represents
currently the “gold standard”(Table 2).74,76,77 The HIMS
(https://www.perkins.org.au/wacha/our-research/mens/
Table 2. Main characteristics of large cohort studies investigating sex steroids and aging.
Study
Period
(yrs)
Study
Design
Sex M,
F
Subjects
(N) Age
Span
(yrs) T assay
Sex Steroids
as Main Aim Primary End Point^ ^ Country
BLSA 1958- PLOC-B M,F n.a. >20 58 IAs no General overview on
aging
Baltimore (USA)
MMAS 1987–2004 PLOC-B M 1709 40–70 17 IAs yes Hormone levels and ED Boston (USA)
MrOS 2000–2006 MC-PLOC-
B
M »11000 >65 6 LC-MS/MS no Fracture risk factors USA, Sweden, Hong-
Kong
EMAS 2003–2010 MC-PLOC-
B
M 3369 40–79 7 LC-MS/MS
IAs
yes Anabolic hormones
changes and health
outcomes
Some EU Countries^
RBS 1972- PLOC-B M,F 1094 >30 44 IAs no Heart disease risk factors Southern California
(USA)
InCHIANTI 1998- PLOC-B M,F 601 >65 18 IAs no Physical function in aging Tuscany (Italy)
Tromsø 1974–2008 PLOC-B M,F 6595 n.d. 34 IAs no CV-related mortality Tromsø (Norway)
CHAMP 2005- PLOC-B M 1705 >70 11 LC-MS/MS no Major geriatric syndromes Sydney (Australia)
HIMS 1996–2004 P-BRT M 12203 >65 8 IAs no Aortic aneurysm in aging Perth (Australia)
Notes. M: males; F: females; Number of male participants at the beginning of the study; For some studies methods for T assay varied overtime during the
long period of study protocol; U^K, Italy, Belgium, Poland, Sweden, Spain, Hungary, Estonia; EU: European; ^^ The main end point to be investigated
in relation to aging; PLOC-B: Prospective, Longitudinal, Observational, Community-Based Study; MC-PLOC-B: MultiCenter, Prospective, Longitudinal,
Observational, Community-Based Study; P-BRT: Population-Based, Randomized, Trial; n.d.: not detectable at any analysis; CV: cardiovascular; ED: erectile
dysfunction.
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mens-health-1/) was initially realized as a trial of screen-
ing for abdominal aortic aneurysms in Perth, Australia,
but blood samples were obtained since baseline from all
participants, thus it was possible to correlate their
gonadal status to different physical, metabolic and psy-
chological aspects.78 However, the study was not
addressed specifically to reach endocrinological end-
points78 (Table 2).
Age-related sex steroids changes across cohort studies
Almost all the studies found a decline of total serum T
with advancing age (Table 3, Table 4). The BLSA esti-
mated a decline of total serum T around 3.2 ng/dl per
year,4,79 this esteem being around 1.9 pg/ml per year in
the RBS,80 while the first data coming from the MMAS
reported a decline of serum total and free T of about
0.4% and 1.2% per year, respectively53 (Table 3). More
recently, the CHAMP study showed a decline of serum
total T around 2% per year81 (Table 3).
The EMAS results have confirmed, in the last years,
the data concerning the progressive decline in aging men
of serum total T, free T, and E2
82, as well as those con-
cerning the rise of SHBG with aging83 (Table 3).
The CHAMP recently replicated these results except
for a surprising increase of E2
81 (Table 3).
In the HIMS study, serum free T significantly
decreased with increasing age, while total serum T levels
seemed to remain stable; this is probably due to the
important increase of SHBG in older age, which could
justify the persistence of stable total T levels84 (Table 3).
In line with other studies, also the RBS showed a
decline of both total and bioavailable serum T levels with
aging80 (Table 3). In particular, bioavailable serum T lev-
els decreased more (18.5 pg/ml) than serum total T in
aging men mainly due to the corresponding increase of
SHBG with age,59,80,85 (Table 3).
Even though the MrOS did not provide data on the
trajectories of sex steroids overtime, it indirectly has con-
firmed that both serum T and E2 decline with advancing
age86,87 (Table 3). By dividing participants according to
quartiles of SHBG and sex steroids, in fact, their age was
higher in the higher quartiles of serum SHBG88 and in
the lower quartiles of both serum E2
86 and free T87.
Vice versa no data on the decline of sex steroids were
available in the InChianti study even though measure-
ments of total T, E2 and SHBG serum levels were avail-
able for the majority of men67,70,85 in this study
hormonal data were mainly used for investigating the
association between circulating sex steroids and several
conditions that are common in aging69,68,67,70,66(Table 3).
Male hypogonadism across cohort studies
The prevalence of biochemical hypogonadism seems
always to increase with advancing age, being indepen-
dently from the study considered, at the lowest in men
younger than 49 y and progressively increasing through
decades, with the highest prevalence being in men in
Table 4. Main similarities and differences of large longitudinal, cohort studies.
STRONG DISCREPANCIES WEAK DISCREPANCIES WEAK ANALOGIES STRONG ANALOGIES
Hormonal Trajectories
– – # serum total and free E2 #serum total T
with advancing age ##serum free T
##bioavailable T
"serum SHBG
with advancing age
Consequences of Hormonal Changes Related to Male Aging
 Association between low T
and low BMD.
 Association between T and cognitive
functions.
 Association between low T and CV
risk factors’ increase.
 Serum T is directly related to sexual
function, especially libido.
 Association between low T
and depression.
 Association between low T and
atherosclerosis.
 Association between low T and
increased CV risk.
 Association between low T and
increased all-causes mortality risk.
 Association between low T
and CV-related mortality.
 Relationship between hypogonadism
and frailty development.
 Association between low T and poor
health status.
 Healthy life-style correlates with
higher T levels/prevention of T
decline.
 Relationship between T and
physical performance.
 Correlation between serum T
measured by LC-MS/MS and by AIs.
 Association between low T and low
hemoglobin.
 Association between low T and
both overweight and obesity.
 Relationship between T and
prostate cancer.
 Association between low T and
impaired pulmonary function.
 High T correlates with better lean
mass, and muscle strength.
 Association between low T and
both metabolic syndrome and
type 2 diabetes.
 Association between low T and/or
low E2 and frailty.
 Low T correlates with erectile
dysfunction.
 Serum E2 correlates with BMD.
 Serum E2 is inversely related to
fracture risk.
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their 80s.4,8,82,83,89,90 However, according to a more
recent analysis, total serum T levels seem to be quite sta-
ble until the age of 70 years, after that there would be a
progressive, significant decline, while the bioavailable
serum T seems to decline more linearly with aging.79
In line with other studies,3,8,89,90 in the Tromsø study
the investigation of hormonal changes with aging
resulted in the finding of lower serum T levels and higher
gonadotropins levels in older men60 (Table 3), even
though the measurement of gonadotropins in aging men
is scarcely helpful in predicting the future development
of hypogonadism91 (Table 3).
Several cutoffs for male hypogonadism have been sug-
gested on the basis of the results of these large cohort
studies. The MMAS study has suggested the following
age-related cutoffs for serum total T: 251, 216, 196, and
156 ng/dL (8.7, 7.5, 6.8, and 5.4 nmol/L) for men in their
40s, 50s, 60, and 70s, respectively.61 Many data about
aging and gonadal status arose from the EMAS and the
identification and definition of the LOH as a clinical con-
dition has been one of the biggest results.3 LOH has been
in fact defined as a condition characterized by 3 sexual
symptoms (decreased sexual thoughts, decreased fre-
quency of morning erections and erectile dysfunction)
together with total serum T less than 317 ng/dL (11 nml/
L) and free T less than 63,4 pg/mL (220 pmol/L).3
According to the grade of serum T decrease, LOH can be
considered as moderate or severe. In particular, total
serum T concentrations lower than or equal to 230 ng/
dL (8 nmol/L) have been associated with worse sexual
functioning and higher rates of erectile dysfunction.92
Main outcomes of cohort studies
The comparison of such kind of large cohort studies
clearly remarks the great heterogeneity of outcomes,
which differ for each study according to the peculiarity
of the study design and the number and type of clinical
and laboratory data collected. While data on trajectories
of sex steroids are almost available in all studies (see the
paragraph above), information about the relationships
among circulating sex steroids and/or various clinical
aspects and physiological changes related to aging
become patchy when moving across the various studies
(Table 3).
While changes in circulating total, free, and bioavail-
able T, E2, and SHBG are unidirectional in almost all the
studies, several other outcomes were not replicated, thus
leading to conflicting results when different studies are
compared each other (Table 3, Table 4).
The relationship between the decline of serum T and
the worsening of sexual function has been investigated
and confirmed by most of these studies (Table 3). The
MMAS,93,94 the CHAMP,74 and the EMAS.3,95 provided
a lot of data on the relationship between gonadal status
and sexual desire, sexual function, and erectile function
in middle-aged to older men (Table 3), suggesting that
loss of sexual desire, but not erectile function, is strictly
related to low T in aging men96 and could be predictive
for the development of erectile dysfunction (ED)94 Thus,
low serum T (the main component of low desire) is indi-
rectly related to the onset of ED and to impaired male
sexual function.47 In particular, in the EMAS study lower
serum free T levels have been more strongly associated
with severe sexual dysfunction (such as increased erectile
dysfunction and lower masturbation frequency).83,92
Less data are available on sexual function in the BLSA
and MrOS studies97 (Table 3).
Overweight and obesity are strongly associated to the
decline of both total serum T and SHBG in several stud-
ies such as the MMAS,37,98,99 the BLSA,4 the EMAS,100
and the Tromsø,101,102,103 studies (Table 3). Changes in
body composition lead to an increased risk of developing
both the metabolic syndrome104 dyslipidemia,65,105,106
and diabetes107 (Table 3).
Metabolic syndrome was associated to low serum T and/
or low SHBG in the BLSA,41 HIMS,108,109 InChianti,68,67
Tromsø,110,111,112 and RBS.65,105,106 studies, but not in the
CHAMP study, the latter showing an association between
lower SHBG levels, but not T, and the development of meta-
bolic syndrome76 (Table 3).
The EMAS study showed that weight loss is associated
to an increase, while weight gain to a decrease in both
total and free serum T, with the same association persist-
ing by considering waist circumference82 As previously
reported, obesity probably determines an impairment of
the hypothalamic-pituitary function, leading to lower LH
incretion and finally to hypogonadotropic hypogonad-
ism. This evidence is very important because it suggests
that weight management and obesity avoidance could be
useful to prevent T decline.82,100 Furthermore, the rela-
tionship between weight and T is probably bidirectional,
since hypogonadism promotes fat accumulation and low
total and free serum T levels have been associated with an
increased risk of developing metabolic syndrome.18
Data on the relationship between T and the cardiovas-
cular (CV) system are available from the BLSA,113 the
MrOS,114 the Tromsø,110,111,112 and the RBS,115 showing
that hypertension is associated to low serum T (Table 3).
As suggested by the Tromsø study, smoking, overweight,
and obesity represent possible confounding factors when
evaluating the relationship between serum T and CV dis-
eases in cohort studies.116
The major role of serum estrogens on bone health has
been suggested by almost all the studies,117 serum E2 and
T being directly correlated with bone mineral density
(BMD). This correlation is particularly strong for free
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serum E2
86,118,119. Furthermore, the MrOS has shown
that low serum T together with high SHBG levels and
low serum estradiol levels are associated with increased
risk of non-vertebral fracture.117 On the other hand, data
about the effects of serum T on BMD remain conflicting
since the association between low serum T and lower
BMD has not been demonstrated in all studies, such as
the MrOS.120 In the EMAS study, however, men with
overt hypogonadism (total T<230 ng/dL [8 nml/L])
show worse serum parameters of bone health compared
with eugonadal men.118,121 Probably, T contributes to
bone health through its effect on muscle mass (and the
consequent mechanical load on bone) and via aromatiza-
tion to estrogens.42,48,121 Thus, low circulating levels of T
result in parallel in low serum E2
42,48. Differently from
the majority of studies, the CHAMP study did not find
any association among serum T, E2, SHBG, and bone
health,122 on one hand, and, on the other hand, the
Tromsø did not find any association between sex steroids
and both BMD71 and fracture risk.72
Low total T levels were associated with lower hemo-
globin levels in the InCHianti study similarly to EMAS,89
suggesting that the effects of low T on hemoglobin
should be carefully evaluated in older men due to the
fact that anemia is one of the strongest markers of
frailty69
Not all studies investigated physical performance and
both the muscular mass and strength in relation to circu-
lating sex steroids.77,123,124 (Table 3). Physical perfor-
mance was only weakly associated to serum T in the
MMAS125 In regard to body composition, total serum T
is related directly to lean mass, playing a possible protec-
tive role in healthy aging, since a better muscular func-
tion helps preventing falls, fractures, and frailty to some
extent, as suggested by the MrOS study.126
Low total and free serum T levels have been also asso-
ciated with frailty in the HIMS,127 CHAMP,128 and the
MrOS studies.129 In addition, men with poor health sta-
tus, in particular those who had a stroke or a cancer diag-
nosis, had lower levels of both total and free serum T
levels in the Tromsø study,91 while self reported worse
health status was associated to low T in the CHAMP75
(Table 3). Otherwise, in the MMAS a good health and
the absence of chronic illness were both associated with
a less important decline of serum T37 (Table 3).
Not all the studies investigated neuropsychological
correlates of age-related T decline. The BLSA studied the
possible correlation between androgens and cognitive
function leading to a possible role of T in preventing cog-
nitive dysfunction and depressive mood.130-132 These
data on mood105 and cognition were also replicated by
the RBS study,133 and the HIMS134; in particular the lat-
ter showed an increased risk of developing depressive
symptoms in association to low serum total T135
(Table 3). Conversely, no relationship between sex ste-
roids and cognition was found in other studies, such as
the MMAS,136 the CHAMP,137 and the MrOS.97
In these large cohort studies, low serum free T was
almost constantly associated with an increased all-causes
mortality risk, this association was found by the
HIMS,138 CHAMP,81 MMAS,139 EMAS,95 RBS,119
Tromsø,140 and MrOS141 studies. In the MrOS the mor-
tality risk appeared to be higher when also low serum E2
was present.141 Vice versa, the InChianti study did not
find any association between low baseline free serum T
levels and 6-years mortality risk.66 The association
between low serum T and mortality due to CV events
remains less known since this association was proven
only by the HIMS study.138
Lesson learnt from large cohort studies
The integrated analysis of data provided by these large
longitudinal studies allows highlighting several issues
that are of concern for research advancement, methodo-
logical outcome and finally for clinical practice.
At the beginning most of these longitudinal studies
provided first analyses based on cross-sectional
data.53,142 The longitudinal design of the studies came up
progressively as the studies aged together with their par-
ticipants. First cross-sectional data did not find changes
in circulating sex steroids between older and younger
participants.142 Subsequently, the decline of sex steroids
was unequivocally proved when the data from longitudi-
nal analyses became available. Accordingly, the most
important result reached by all the studies is to demon-
stratethe serum T decline with advancing age. Particu-
larly, both free and total serum T levels tend to decrease;
the latter decreases lesser than the former as a conse-
quence of the progressive increase of SHBG with aging
(Table 4). Also the modification of SHBG has been con-
firmed by all the studies (Table 4).
In all studies that have investigated male sexuality,
serum T resulted inversely related to sexual desire and to
some extent to sexual activity and erectile function too
(Table 4). Another concordant result is the association
between low serum T and obesity, metabolic comorbid-
ities such as the metabolic syndrome, and type 2 diabetes
(Table 4).
Among other clinical aspects that are associated to
serum T lowering with advancing age, all-cause mortal-
ity, body composition changes, especially overweight ad
obesity as well as metabolis syndrome and diabetes, all
have been over and over again associated to T decline in
aging (Table 4).
The methodological approach used for T measure-
ment has changed overtime according to advancements
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in this field in all the studies (Table 4). At present, the
gold standard LC-MS/MS is being used in all studies,
while at the beginning of the studies sex steroids were
measured by IAs. This implies that the comparison of
the results coming from different studies as well as the
results of the same study obtained in different periods by
using different assay methods remain challenging. There
is not consensus about the correlation between total
serum T measured by MS and IAs among studies since
some studies find a good correlation while others find
discordant measurements (Table 4). This issue is impor-
tant when data coming from research studies like these
are transposed and applied to daily clinical practice since
IAs are commonly employed, at present, in clinical
laboratories.
A lesser degree of certainty has been reached regard-
ing the association between T lowering with advancing
age and CV diseases, increse iıog CV risk, ED, and
impaired bone health (Table 4).
The most controversial issues concern the association
of T decline to impaired physical performance, neuro-
psychological issues, CV-related mortality, and cancer
risk (Table 4).
Table 4 summarizes in detail the main analogies and
discrepancies regarding the issues that have been mostly
investigated by large cohort studies till now (Table 4).
Significance of age-related serum T changes in aging
men
The decline of serum T with advancing age has been tradi-
tionally interpreted as the male counterpart of menopause.
In other words, the decrease of T was considered as a condi-
tion due to the aging of gonadal function. In this old view,
the term andropause was considered as a physiological event
like menopause in females143-145 with the unique difference
that the ovaries stop to function suddenly while the testes
loose their function gradually (Fig. 1).
At present, it has not defined whether the decline of
serum T in the elderly represents a physiological process
of aging or whether this event should be considered as
pathological. In 2004 Snyder stated that ‘an essential but
still unanswered question is whether this decrease in the
testosterone concentration is physiologic, perhaps convey-
ing a benefit, or pathologic, causing harm’.146 Today, this
point remains still crucial in order to establish if a strat-
egy that is effective in counteracting serum T decline
should be set up or if treating serum T decline maybe
potentially harmful. With this in view, the identification
of patients with low serum T that might beneficiate of
replacement therapy on one hand and the recognition of
those for which therapy is not indicated is challenging.
All these issues usually converge on the practical point
concerning how to diagnose LOH.147
The clinical diagnosis of LOH: lights and shadows
Recently, there is consensus among endocrinologists,
andrologists, and urologists about the fact that the finding
of biochemical T deficiency does not necessarily correspond
to LOH in middle-aged-to-older men.12,25,38-40,49,147,148
Accordingly, lower serum T in older men should not be
considered “per se” significant, but it acquires a clinical value
in men with concomitant signs and symptoms of T defi-
ciency, a condition known as hypogonadism.3,12,25,38,40,49,148
Some aspects related to the diagnosis of hypogonadism do
not differ according to the patients’ age (e.g., categories of
hypogonadism), while for other aspects (e.g., causes of
hypogonadism, signs and symptoms, and serum T thresh-
olds) the patients’ age does matter.40,49,149,150
Classification of LOH
In general, 2 main forms of hypogonadism can be distin-
guished: (a) primary hypogonadism (or hypergonadotropic
hypogonadism), where the site of origin is the testis and
which is characterized by low T levels with high gonadotro-
pins levels, and (b) secondary hypogonadism (or hypogona-
dotropic hypogonadism), in which there is hypothalamic
and/or pituitary failure causing low gonadotropins produc-
tion and consequent low T levels12,25,49,148 (Fig. 2). Further-
more, among aging men is quite common a condition of
compensated hypogonadism, represented by normal T lev-
els with high gonadotropins levels, whose prevalence
increases with aging and which seems to be a subclinical
condition that could develop in overt, primary hypogonad-
ism overtime90 (Fig. 2). Recently, data coming from the
EMAS study confirm that age is correlated with the develop-
ment of primary hypogonadism, but not with secondary
hypogonadism, the latter being strictly associated to comor-
bidities rather than age.3,151,152
Causes of LOH
In younger men hypogonadism (both hypergonado-
tropic and hypogonadotropic) is usually due to well-
known causes, which can be congenital or acquired, and
the site of origin is easily recognizable.40,49,149,150 Con-
versely, many different factors, some of which are still
not well defined, contribute to the decrease of T produc-
tion in aging men (Table 1). For example, aging “per se”
is known to induce a progressive dysfunction of Leydig
cells, but age-advanced typical chronic comorbidities
(e.g., cancer, chronic obstructive pulmonary disease,
chronic renal failure and chronic liver failure) are also
associated with low serum T (Table 1).6,153 Accordingly,
age and chronic diseases resulted associated to primary
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hypogonadism in the EMAS cohort.151 Thus, low serum
T of the elderly man is often due to both primary and
secondary failure of T secretion. Other factors involved
in serum T declining include bad lifestyle habits, such as
smoking and excessive alcohol intake, and chronic thera-
pies with opiates and glucocorticoids, increasingly used
to treat elderly population (Table 1).6 Several clinical
conditions (e.g., chronic or acute diseases) are associated
to hypogonadism in aging men, some of them cause sec-
ondary hypogonadism, which is not related to age and
might be reversible.15,152 In particular, diabetes mellitus,
obesity and metabolic syndrome seem to play a major
role especially in decreasing gonadotropin levels, leading
to secondary hypogonadism (Table 1).90,147 Other factors
involved in serum T declining include bad lifestyle hab-
its, such as smoking and excessive alcohol intake, and
chronic therapies with opiates and glucocorticoids,
increasingly used to treat elderly population (Table 1).6
Here we summarize the main clinical conditions and dis-
eases linked to hypogonadism.
Hypogonadism and non-infectious comorbidities
Chronic non-infectious diseases. Hypogonadism might
occur in several chronic conditions at any age, but it is self-
evident that this association increases with advancing age as
a consequence of higher probability to develop and/or accu-
mulate newmorbidities during aging.15,91,154
Overweight, obesity, and metabolic disorders (metabolic
syndrome, diabetes, dyslipidemia) are more frequent in
older men and are all associated to low serum T in men, as
already discussed in this article.20,22,40,41,,102,103,105,107,152
Chronic liver diseases, especially cirrhosis and fatty liver
disease,155 are associated to hypogonadism as a consequence
of increased liver production of SHBG and of estrogen
excess and its inhibitory effect on gonadotropins.22
The prevalence of hypogonadism seems to be high in
men with chronic obstructive pulmonary disease
(COPD), especially in middle-aged and elderly men,22,153
ranging from 22 to 69%.156,157 In particular, secondary
hypogonadism is associated to COPD and the severity of
COPD seems to be directly correlated with the degree of
hypogonadism.157 An interesting, not widely investigated
association has been found between low total and free
serum T levels and impaired pulmonary function evalu-
ated by spirometry in the Tromsø study.116 Considering
that oxygen therapy is known to increase T levels in men
with respiratory failure, it seems more likely that poor,
pulmonary function is responsible of lower T levels and
not vice-versa, may be by altering the hypothalamic-
Figure 2. Classification of hypogonadism according to its pathogenesis.
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pituitary function.158 The studies on COPD, however,
are scanty and have been performed on small samples of
patients, thus more data from more studies are still
needed to better characterize hypogonadism in older
men with COPD.22
Male hypogonadism is highly prevalent also in
patients with chronic kidney disease as a consequence of
testicular damage (primary hypogonadism).21,22,159 In
patients who undergo hemodialysis for the first time
hypogonadism do not normalize and tends to worsen,
only renal transplantation being able to restore normal
serum T21,22,159,160.
Several congenital systemic diseases might induce
hypogonadism in the young, adult man and hypogonad-
ism is intended to worsen with advancing age as in the
case of b-thalassemia161 and hemocromatosis.162
Finally, treatments used for systemic chronic diseases
might induce hypogonadism as in the case of rheumatoid
arthritis.22,153 or treatment for cancer22
The issue concerning the relationship existing
between morbidities and LOH is relevant since might to
be bidirectional.40 On one hand, LOH sustains or exacer-
bates morbidities, while, on the other hand, LOH might
be caused by comorbidities and might be reversible if
comorbidities are treated.40 The same hormonal change
occurs in patients with other acute illnesses different
from infectious diseases.163-165 These changes seem to be
part of a mechanism, which is adaptive to poor health
status aiming to counteract the high catabolic state due
to the acute, severe clinical condition. By decreasing the
activity of the pituitary-gonadal axis it is possible to
reduce some body functions (e.g., physical and sexual
activity), thus allowing sparing energy and avoiding
reproduction during a unhealthy condition.165 Since
chronic diseases are associated to hypogonadism in the
male,153,163 it has been postulated that in a part of men
developing T deficiency with advancing age LOH maybe
the consequence of multimorbidity that accumulates in
the aging patient.40 With this in view, a considerable
quote of LOH are not consistent with a clinical condition
of hypogonadism, but represents an epiphenomenon of
a poor health status, which is a common condition in the
elderly.38,40 With this in view, hypogonadism could be
considered as a functional, adaptive mechanism enrolled
in presence of a condition of poor health sta-
tus,40,50,165,166 as it happens in case of acute, severe
illness.
Acute non-infectious diseases. Serum T might fall down
in patients with acute, critical illnesses and normal serum
T levels are restored by the resolution of the acute clinical
condition.164,167,168 This condition occurs regardless the
nature of the acute illness,163,164,169,170 it is associated to
the severity of patients’s clinical condition,163,168 and
might be transitory and reversible.167,171 This mechanism
based on a strict relationship between patient’s poor
health status and low serum T operates especially in
aging men and share a mechanism involving the hypo-
thalamus and the pituitary resulting in secondary
hypogonadism.3,9,100,152
Aging, hypogonadism, and frailty. As mentioned above,
patient’s poor health status in terms of deteriorated clini-
cal conditions might influence T secretion. In aging men,
however, the more complicated, multidimensional con-
cept named frailty should be also considered.172 Frailty
depends not only by the clinical condition of the
patients, but encompasses also all the physiological and
pathological changes accumulating during aging that
impair patients’ physical performance (e.g., sarcopenia,
osteoporosis, walking disabilities, impairment of visual
acuity) as well as his pshychological status (loss of mem-
ory, depressed mood) and well-being.172-174 All these fac-
tors contribute to frailty and expose the aging man to
experiment harmful events (e.g., falls, progressive reduc-
tion of physical activities).172-174
Frailty is inversely related to serum T in older men, as
substantiated by several studies.15,17,154,175-177 Further-
more, sarcopenia is directly related to low serum T178
and takes part to the physiological process of aging
itself.179-181 Even chronic illnesses are able to induce sar-
copenia.180,182 Thus it is evident that sarcopenia should
be considered as a central player in the relationships
among LOH, frailty, and comorbidities.181
Aging, hypogonadism, and infectious diseases. Data
available on the relationship among aging, hypogonad-
ism, and infectious diseases are scanty. It is well known
that sepsis induces a fall of serum T in men together
with a decrease of serum LH, consisting with a condition
of hypogonadotropic hypogonadism.169,170 (Fig. 2). The
same hormonal change occurs in patients with other
acute illnesses different from infectious diseases163-165
These changes seem to be part of a mechanism, which is
adaptive to poor health status aiming to counteract the
high catabolic state due to the acute, severe clinical con-
dition. By decreasing the activity of the pituitary-gonadal
axis it is possible to reduce some body functions (e.g.,
physical and sexual activity), thus allowing sparing
energy and avoiding reproduction during a unhealthy
condition.165 Since chronic diseases are associated to
hypogonadism in the male,153,163 it has been postulated
that in a part of men developing T deficiency with
advancing age LOH maybe the consequence of multi-
morbidity that accumulates in the aging patient.40
With this in view, a considerable quote of LOH are
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not consistent with a clinical condition of hypogonad-
ism, but represents an epiphenomenon of a poor
health status, which is a common condition in the
elderly.38,40
Among infectious diseases that may interfere with
circulating T, rare testicular infections causing orchitis
usually induce a temporary or permanent primary hypo-
gonadism (hypergonadotropic hypogonadism).183 Con-
versely, chronic viral hepatitis are often related to an
increase of serum total T rather to T deficiency; this con-
dition is due to the rise of SHBG and does not modify
free serum T184.
Hypogonadism and HIV infection. Among HIV
infected-men a process of accelerated aging seems to
take place, deriving from a multifactorial etiology
(immunosenescence, inflammation, multimorbidity);
therefore, HIV infection can be considered a model of
premature aging.185 Accordingly, a premature decline of
serum T has been described in this population.186 The
prevalence of biochemical hypogonadism in HIV-
infected men is around 25% in young-to-middle-aged
men50 and serum T decline in HIV-infected men aged
45–60 y seems to parallel what happens in older men
after 60.50,186 In HIV-infected patients secondary hypo-
gonadism is more common and is associated to fat redis-
tribution and visceral adiposity.50,186 Furthermore, low
levels of serum T are associated with to higher number
of comorbidities and are inversely related to frailty.166
The latter finding does not help in establishing if these
patients are truly hypogonadic or if their low T is related
only to their poor health status.
The diagnosis of hypogonadism in these patients
shares all the problems physicians have with older
men and it is even more difficult due to the fact that
symptoms and signs are much more less specific than
in the general population. Sign and symptoms, espe-
cially those related to sexuality and body composition
changes, overlap, in fact, with those of HIV
infection.50
Finally, SHBG measurements is mandatory in men
with HIV since SHBG alterations are very common in
these patients and might lead to underestimation of
hypogonadism.50
Serum T thresholds for LOH diagnosis. The cut-off of
serum total T below which the diagnosis of overt bio-
chemical hypogonadism could be formulated remains to
be determined. Different studies,3,187,188 clinical guideli-
nes12,25,33,148,154(https://uroweb.org/guideline/male-hypo
gonadism/), expert panels,49 and extensive literature
revision.38-40,147 provided different cutoffs. However, all
the cutoffs fall within the interval of serum total T com-
prised between 180 ng/dL and 300 ng/dL (Table 5).
Since T secretion follows a circadian rhythm, with
peak values in the morning, T measurement should be
performed in the morning, preferably in 2 different occa-
sions12,25,33,38,49,148,154(https://uroweb.org/guideline/
male-hypogonadism/). When serum total T levels are
borderline evaluation of free T can be useful, especially
among older men who physiologically tend to have
increased levels of SHBG33,154 In particular, SHBG mea-
surement is indicated in obese patients and patients with
chronic diseases (e.g., HIV-infection, viral hepatitis).25
Table 5. Serum testosterone (T) cutoffs suggested for the diagnosis of LOH.
Cutoff Provider Biochemical Hypogonadism Gray Area (Mild Biochemical Hypogonadism) Normal T
Serum total T ng/dL (nmol/L)
Endocrine Society Guidelines <300 (<10.4) – >300 (>10.4)
AACE Guidelines 202(<7) – >202 (>7.0)
ISA, ISSAM, EAU, EAA, & ASA Guidelines <231(<8) 231 < T < 346 (8 < T < 12.0) >346 (>12.0)
EMAS Study <317(<11) – >317(>11.0)
HIMS Study (<5th percentile) <185(<6.4) – >185(>6.4)
MMAS Study
40–49 yrs <251 (<8.7) – >251 (>8.7)
50–59 yrs <216 (<7.5) >216 (>7.5)
60–69 yrs <196 (<6.8) >196 (>6.8)
>70 yrs <156 (<5.4) >156 (>5.4)
Australian Clinical Pathology Laboratories <185 (<6.4) – >185 (>6.4)
Serum free T pg/mL (pmol/L)
ISA, ISSAM, EAU, EAA, & ASA Guidelines <64.8 (<225) – >64.8 (>225)
EMAS Study <63,4 (<220) – >63.4(>220)
https://uroweb.org/guideline/male-hypogonadism/
Notes. T: testosterone; AACE: American Association of Clinical Endocrinologists; ISA: International Society of Andrology; ISSAM: International Society for the Study
of the Aging Male; EAU: European Association of Urology, EAA: European Academy of Andrology; ASA: American Society of Andrology; EMAS: The European
Male Aging Study; MMAS: The Massachusetts Male Aging Study.
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It is important to remark, however, that common lab-
oratory assays used for free T measurement are not reli-
able and calculation of free T starting from total T,
albumin and SHBG with equations that have been vali-
dated should be preferred.3,13,14,25,148 Some guidelines12
or large longitudinal studies3 have provided thresholds
also for calculated serum free T (http://www.issam.ch/
freetesto.htm) (Table 5).
Signs and symptoms of hypogonadism. The diagnosis of
hypogonadism requires both biochemical measurements
and clinical features12,25,33,38,49,148,154(https://uroweb.org/
guideline/male-hypogonadism/). Since very often the
symptoms suggestive of low T are attributed to age
among older men, recognizing hypogonadism is not
easy.15,148
The interview is essential in order to disclose symptoms
of hypogonadism, which belongmainly to sexual and physi-
cal functions.12,25,33,38,49,148,154 (Fig. 3). The most specific
symptoms related to the decrease of serum T are: reduced
sexual desire (libido) and activity, decreased spontaneous
erections in the morning, erectile dysfunction, reduced
shaving frequency, decreased energy and vitality, and occa-
sionally hot flushes3,12,25,38-40,49,147,148(Fig. 3). Other
symptoms are less specific (e.g., depressed mood and
reducedmuscle strength)12,25,33,38,49,148,154 (Fig. 3).
At physical examination, signs suggestive of
hypogonadism should be investigated, such as reduced
pubic and axillary hair, reduced testicular size and
volume of ejaculation12,25,33,38,49,148,154 Figure 3
summarizes sign of hypogonadism according with to
their specificity.3,12,25,38-40,49,147,148
In conclusion, the best way for the diagnosis is to com-
bine serum T (total or free) with the symptoms,3,38 regard-
ing at LH as an adjunctive information useful to obtain a
comprehensive picture of the pituitary gonadal axis and to
find patients at higher risk to develop hypogonadism in the
next future (compensated hypogonadism)90 (Figure 2).
Other examinations. If low serum total T is confirmed,
measurement of serum LH and follicle-stimulating hor-
mone (FSH) is recommended in order to identify primary
or secondary hypogonadism (Figure 2).12,25,33,38,49,148,154
Both the conditions can be found in older men without spe-
cific endocrinological causes, nonetheless when LH and
FSH levels are very low and suggest a central origin of hypo-
gonadism, a global evaluation of pituitary function should
be taken to exclude hypopituitarism.25,148
Figure 3. Signs and symptoms of late-onset hypogonadism according to their specificity.
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Finally, bone densitometry should be performed in
case of low T, because hypogonadism often is responsible
for osteopenia, osteoporosis, and increased fracture risk
in older men.48
Testosterone replacement treatment: Certain
knowledge and controversies
Since many factors involved in low T onset are reversible,
life-style modifications, such as smoke abolition and
moderate alcohol consumption, physical activity and
weight loss should be suggested not only to avoid hypo-
gonadism, but also for general well-being in older age.147
Similarly, the resolution of acute illnesses.40,164,165 or the
improvement of chronic diseases that might cause hypo-
gonadism153 generally improve serum T as well as clini-
cal condition in older men171
Patients who are candidate to receive T replacement
are those with documented LOH, concomitant symp-
toms and/or signs of low T (especially sexual symptoms)
and no contraindication to T treatment.12,25,33,38,49,148,154
Treatment should be tailored according with to patient’s
health status and expectations after having considered
the potential risk and after having informed the patients
about possible risk and benefits.12,25,33,38,49,148,154 Evi-
dence coming from randomized trials in men older than
60 y is, in fact, still lacking and future large, prospective
studies are required and worthwhile.189
At present, there is consensus against T treatment in
men with a serum total T above 346 ng/dL (12 nmol/
L).12,38,49,154 or values of serum T very close to 346 ng/dL
(https://uroweb.org/guideline/male-hypogonadism/).
T treatment is effective in improving sexual function,
but this effect is not evident in men with normal
serum T190. Other beneficial effects are related to the
improvement of body composition and metabolic
outcome40
It has been supposed that T treatment might increase CV
risk (http://www.fda.gov/Drugs/DrugSafety/ucm436259.
htm) on the basis of CV events reported in some of the T
trials.189,191-194 However, at present 4 different meta-
analyses have not found this association to be consis-
tent,194-197 while only one confirmed an increased CV
risk due to T treatment.198
Contraindications are documented prostate and breast
cancer, and strong caution should be used when hematocrit
is increased (>50%).12,25,33,38,49,148,154 Other aspects that
should be considered are congestive heart failure, sleep
apnea, benign prostatic hyperplasia and a prostate specific
antigen (PSA) >4 ng/mL.12,25,33,38,49,148,154 Furthermore,
patients with a recent (within 6 months) history of CV
events should not be considered as candidate to receive T
replacement treatment.38,40,49,189
The patient should be informed about potential bene-
fits that involve mainly sexual desire and function, vigor,
body composition changes and prevention of bone loss.
At the same time, patient should be aware that T treat-
ment in older men might be harmful and that evidence
in favor of its safety is not of good quality.
Unresolved issues
Sexual symptoms are the most useful to prompt the diag-
nosis of LOH, but they are also difficult to unmask in the
consistent percentage of patients (especially older men)
who are reluctant to talk about them with physicians.199
In addition, even physicians are less prone to interview
aging men about their sexuality.200
We know that amongmenwith a diagnosis of LOH there
are false positive and that this diagnosis is probably over-
looked in other men (false negative). However, it is very dif-
ficult to have precise data concerning the accuracy of LOH
diagnosis due to the lack of certain diagnostic criteria.
Concerning the diagnosis of LOH, there is still a gap
of knowledge about the significance of great serum T
decrease from the baseline overtime (e.g., 50%) leading
to a serum value still in the range of eugonadism, but
much lower than in the past. It is possible that patients
with this kind of serum T decline trajectory become truly
hypogonadal and already display sign and symptoms of
hypogonadism.38 Furthermore, data on the natural his-
tory of LOH are scanty.171
From literature we know that LOH might be revers-
ible in about half of the patients,171 but at present we are
not able to predict, among patients with LOH, who will
return to normal androgenization, except for those
patients who are obese or overweight and loose
weight.147
In the field of geriatrics is getting growing importance
the concept of frailty, which is defined as a condition of
vulnerability to stressing events. The condition of frailty
derives from accumulation of deficits in multiple physio-
logical systems and can be quantified by a frailty index.
At present, the impact of T decline on frailty remains to
be determined. Accordingly, it is not clear if T treatment
is able to improve or worsen frailty in older men. Simi-
larly, the potential for T treatment to be harmful in sick
older men or in men with HIV infection and a poor
health status remains an unsolved issue.189
At present, no association between serum T and life
expectancy was found by comparing long-lived with short-
lived subjects.201 However, differences in lifespan between
men and women suggest a putative role of sex hormones on
longevity.202What we know is that lifespanwas not different
between singers castrated before puberty and non-castrated
singers, suggesting that T does not influence longevity.203 T,
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probably might protect centrally from the effects of stress by
mitigating the central cascade of events induced by the
exposure to stress, while women aremore exposed the nega-
tive effect of stress.204 How much gender differences in the
exposure to sex steroids at any age are involved in determin-
ing longevity and the response to stress remains to be estab-
lished in detail.202,204
Conclusions
The decline of sex steroids with advancing age depends
on gender and interindividual differences. In men physi-
ological changes should be differentiated from pathologi-
cal low serum T and the coupling low serum T with
hypogonadism-related signs and symptoms is a good
strategy to diagnose LOH and to identify patients who
might beneficiate from T replacement. However, the
specificity of symptoms of hypogonadism is low and
measurements of serum T insidious, thus all these factors
increase the risk of misdiagnosis. The presence/absence
of concomitant acute or chronic illnesses could lead the
physician avoiding misdiagnosis and overtreatment.
Patients’ health status, in fact, should be taken into
account prior to start T treatment to prevent adverse
events that are more common in men with poor clinical
conditions. Replacement treatment might be effective in
improving sexual function, body composition, metabolic
outcome, and vitality. In older men T treatment is not
based on good evidence and the patient should be
informed about the lack of proven beneficial effects as
well as on the possible side effects and adverse events.
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